Eli Lilly joins SNM initiative

Mar 25, 2010

Pharmaceutical giant Eli Lilly of Indianapolis has enrolled in SNM's Clinical Trials Network to facilitate the development of therapeutic medicines.

The SNM Clinical Trials Network is designed to address the need for validated imaging biomarkers for the development and registration of investigational therapeutics. Since its creation in October 2008, more than 200 imaging sites and manufacturers in the U.S., Europe, and Asia have joined the network.

The network will apply for and hold investigational new drug (IND) applications for cross-reference in multicenter clinical trials of investigational therapeutics that require INDs for imaging agents to assess response to treatment or to stratify patients for enrollment in clinical trials.

The network plans to roll out the first clinical trial in 2010.

SNM summit advances molecular imaging, February 2, 2010

SNM supports SGR rate fix, December 23, 2009

SNM contests proposed CMS payment rules, November 6, 2009

Acceleware scores Eli Lilly contract, June 4, 2008

GE, Lilly join forces, October 1, 2007

$ChatGPT powered by GPT-4 and using DALL-E−3 was asked to generate an image for teaching purposes that demonstrated: a nuclear medicine bone scan with skeletal metastases (top left); coronary artery disease (top right); an F-18 FDG-PET scan of the brain with Alzheimer's disease (bottom left); and an x-ray showing a fracture (bottom right). These are misleading for educational purposes and for patients who may be searching for information. Image and caption courtesy of Radiography.$